Received May 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 72AB2 | — |
Priorix was administered via intramuscular; This non-serious case was reported by a nurse via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a 39-year-old male patient who received MMR (Priorix) (batch number 72AB2) for prophylaxis. On 14-MAY-2025, the patient received Priorix. On 14-MAY-2025, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: Priorix was administered via intramuscular). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 16-MAY-2025 Nurse reported that Priorix was administered via intramuscular injection to a patient, which led to subcutaneous injection formulation administered by other route.